HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical firm specializing in immunological innovation, has officially divested its oncology immunotherapy programs to NeoTrail Therapeutics, Inc. The asset transfer agreement was executed on January 28, 2026, with expected completion targeted for